AU6408586A - Novel lipoprotein-based drug-delivery systems - Google Patents

Novel lipoprotein-based drug-delivery systems

Info

Publication number
AU6408586A
AU6408586A AU64085/86A AU6408586A AU6408586A AU 6408586 A AU6408586 A AU 6408586A AU 64085/86 A AU64085/86 A AU 64085/86A AU 6408586 A AU6408586 A AU 6408586A AU 6408586 A AU6408586 A AU 6408586A
Authority
AU
Australia
Prior art keywords
delivery systems
based drug
novel lipoprotein
lipoprotein
novel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU64085/86A
Inventor
John P. Kane
Andrew A. Protter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biotechnology Research Partners Ltd
Original Assignee
Biotechnology Research Partners Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotechnology Research Partners Ltd filed Critical Biotechnology Research Partners Ltd
Publication of AU6408586A publication Critical patent/AU6408586A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1275—Lipoproteins; Chylomicrons; Artificial HDL, LDL, VLDL, protein-free species thereof; Precursors thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
AU64085/86A 1985-10-03 1986-10-02 Novel lipoprotein-based drug-delivery systems Abandoned AU6408586A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78378785A 1985-10-03 1985-10-03
US783787 1985-10-03

Publications (1)

Publication Number Publication Date
AU6408586A true AU6408586A (en) 1987-04-24

Family

ID=25130391

Family Applications (1)

Application Number Title Priority Date Filing Date
AU64085/86A Abandoned AU6408586A (en) 1985-10-03 1986-10-02 Novel lipoprotein-based drug-delivery systems

Country Status (3)

Country Link
EP (1) EP0238645A1 (en)
AU (1) AU6408586A (en)
WO (1) WO1987002061A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU583402B2 (en) * 1985-06-17 1989-04-27 Oncholab A.B. Method for the production of a macromolecular carrier loaded with a biologically active substance
AU596096B2 (en) * 1985-03-11 1990-04-26 Scripps Clinic And Research Foundation A diagnostic assay for the presence of apolipoproteins associated with plasma high density lipoproteins

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987002062A1 (en) * 1985-10-04 1987-04-09 Biotechnology Research Partners, Ltd. Recombinant apolipoproteins and methods
GB8717791D0 (en) * 1987-07-28 1987-09-03 Baralle F E Immunoassay method
EP0347915A3 (en) * 1988-06-23 1991-03-20 The Rockefeller University Method and agents for inhibiting low density lipoprotein synthesis
CA2086679A1 (en) * 1990-07-05 1992-01-06 Hermanus A. M. Verheul Receptor directed-toxin conjugates
EP0600875A4 (en) * 1991-06-26 1995-01-25 Bio Technology General Corp Purification of recombinant apolipoprotein e from bacteria.
DE69226197T2 (en) * 1991-11-08 1999-02-11 Somatogen Inc HEMOGLOBINE AS A MEDICINE DELIVERY SYSTEM
EP1236473A3 (en) * 1992-04-03 2003-01-15 The Regents Of The University Of California Self-assembling polynucleotide delivery system
EP0586094A1 (en) * 1992-08-03 1994-03-09 Wisconsin Alumni Research Foundation Soluble LDL receptor and gene
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US6051429A (en) 1995-06-07 2000-04-18 Life Technologies, Inc. Peptide-enhanced cationic lipid transfections
US6344436B1 (en) * 1996-01-08 2002-02-05 Baylor College Of Medicine Lipophilic peptides for macromolecule delivery
GB9620153D0 (en) * 1996-09-27 1996-11-13 Univ Strathclyde Non-naturally occurring lipoprotein particle
WO1998024808A2 (en) * 1996-12-06 1998-06-11 THE UNITED STATES OF AMERICA represented by THE SECRETARY DEPARTMENT OF HEALTH & HUMAN SERVICES, THE NATIONAL INSTITUTES OF HEALTH INHIBITION OF IgE-MEDIATED ALLERGIES BY A HUMAN IgE-DERIVED OLIGOPEPTIDE
US6635623B1 (en) 1997-06-13 2003-10-21 Baylor College Of Medicine Lipoproteins as nucleic acid vectors
DE19745950A1 (en) * 1997-10-17 1999-04-22 Dds Drug Delivery Service Ges Drug carrier particle for site specific drug delivery, especially to CNS
EP1090132A1 (en) * 1998-06-26 2001-04-11 PPL Therapeutics (Scotland) Limited Methods for production of recombinant polypeptides
AU772847B2 (en) 1998-11-12 2004-05-06 Invitrogen Corporation Transfection reagents
WO2001082972A2 (en) * 2000-04-23 2001-11-08 Arizeke Pharmaceuticals, Inc. Compositions comprising carriers and transportable complexes
WO2004050062A2 (en) 2002-12-03 2004-06-17 Blanchette Rockefeller Neurosciences Institute Artificial low-density lipoprotein carriers for transport of substances across the blood-brain barrier
US7803400B2 (en) 2002-12-03 2010-09-28 Blanchette Rockefeller Neurosciences Institute Artificial low-density lipoprotein carriers for transport of substances across the blood-brain barrier
WO2004069207A2 (en) * 2003-02-04 2004-08-19 University Of Connecticut Health Center Immunogenic cd91 ligand-antigenic molecule complexes and fusion proteins
WO2005014823A2 (en) * 2003-08-05 2005-02-17 Wisconsin Alumni Research Foundation Targeted carrier fusions for delivery of chemotherapeutic agents
US8252338B2 (en) * 2005-11-10 2012-08-28 The Regents Of The University Of California Synthetic LDL as targeted drug delivery vehicle
RU2567667C2 (en) * 2008-06-13 2015-11-10 Проекто Де Биомедисина Сима, С.Л. Conjugates for administering biologically active compounds
WO2011044545A2 (en) * 2009-10-09 2011-04-14 Sigalov Alexander B Methods and compositions for targeted imaging
ES2463016T3 (en) * 2009-12-11 2014-05-27 Proyecto De Biomedicina Cima, S.L. Conjugates and compositions for immunotherapy and anti-tumor treatment
EP3169310A1 (en) 2014-07-15 2017-05-24 Life Technologies Corporation Compositions with lipid aggregates and methods for efficient delivery of molecules to cells

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5470384A (en) * 1977-08-22 1979-06-06 Inst Obu Kiyansaa Risaachi Roi High molecular complex
US4411994A (en) * 1978-06-08 1983-10-25 The President And Fellows Of Harvard College Protein synthesis
US4429008B1 (en) * 1981-12-10 1995-05-16 Univ California Thiol reactive liposomes

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU596096B2 (en) * 1985-03-11 1990-04-26 Scripps Clinic And Research Foundation A diagnostic assay for the presence of apolipoproteins associated with plasma high density lipoproteins
AU583402B2 (en) * 1985-06-17 1989-04-27 Oncholab A.B. Method for the production of a macromolecular carrier loaded with a biologically active substance

Also Published As

Publication number Publication date
WO1987002061A1 (en) 1987-04-09
EP0238645A1 (en) 1987-09-30

Similar Documents

Publication Publication Date Title
AU6408586A (en) Novel lipoprotein-based drug-delivery systems
AU5274386A (en) Peptidylaminodiols
AU590362B2 (en) Uv-dosimeter
AU5893286A (en) 2-arylimidazoles
AU5184886A (en) Somatostatines
AU5391286A (en) Trechter
AU569194B2 (en) 5-hydroxy-2-amino-pyrimidines
AU577512B2 (en) m
AU590605B2 (en) Gamma-carbolines
AU5812686A (en) Wingsail systems
AU576731B2 (en) Undermattress
AU586848B2 (en) Spiro-dioxolanes, - dithiolanes and-oxothiolanes
AU5313686A (en) Verktygsstal
AU5519386A (en) Epicondylitis-bandage
AU5514686A (en) Piperazinecarboxamides
AU580512B2 (en) Fdm-tdm transmultiplexing system
AU5848386A (en) Agent delivery systems
AU5392186A (en) Picfilcylinder
AU586903B2 (en) 1-aryl-pyrazoles
AU563024B2 (en) Dihydropyridien
AU586307B2 (en) 1-aryl-pyrazoles
AU5352786A (en) Nasen-kapseln
AU5452286A (en) Wellenenergieanlage
AU4805485A (en) Schlauchbeutelpackung
AU5352386A (en) Vedenalainen tartuntamenetelma ja-valine